Although HER2 heterogeneity in gastric cancer has no commonly agreed definition, it is associated with limited trastuzumab benefit and decreased overall survival in trastuzumab-treated patients, as was suggested by several groups (Haffner et al. 2021; Kaito et al. 2019; Wakatsuki et al. 2018). This evidence concerns the gene ERBB2 and gastric cancer.